Integra LifeSciences Expands Uni-CP(TM) Compression System Product Range for Mid and Hindfoot Reconstruction
PLAINSBORO, N.J., July 13, 2011 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced that it will release a line extension for its Uni-CP™ Compression System. The Uni-CP™ Compression System provides a comprehensive solution for arthrodesis and fracture management for mid and hindfoot reconstruction. The Uni-CP™ product line extension includes a 4-hole U-shape locking plate, designed for second and third metatarsal-cuneiform fusion. The Uni-CP™ Compression System has clearance from the Food and Drug Administration (FDA) in the United States and a CE Mark Certification in the European Union.
"The new line extension is a very exciting opportunity for Integra," said Pete Ligotti, Vice President, Marketing, Integra Extremity Reconstruction. "The U-shape plate is an innovative approach to fixation of the second and third metatarsal cuneiform joints. It comes in three sizes, which gives surgeons a significant addition to their armamentarium, and helps limit uncertainty by accommodating a patient's unique treatment needs."
The Uni-CP™ Compression System currently includes a line of compression plates designed for the correction and stabilization of osteotomies and fusions in the foot. Each product employs a diamond shaped bridge design to provide compression through controlled deformation of the implant by the surgeon. The Uni-CP™ Compression plates use Surfix® locking technology that enables the surgeon to place the plate at the optimal distance from the bone and then lock the screws.
The Uni-CP™ Compression System is sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive, and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com